Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, September 14, 2014

Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.
Earlier this week, Sanofi’s (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.
The extension study enrolled more than 90% of the MS patients who received Lemtrada in either of the phase III CARE-MS I and CARE-MS II studies.

The interim results from the second year of the extension study showed that 74% of the patients from CARE-MS I and 66% of patients from CARE-MS II experienced improved or stable disability as measured by the Expanded Disability Status Scale (:EDSS), for the additional two years beyond the two-year pivotal MS studies. Moreover, nearly 70% of the patients treated with Lemtrada in the pivotal studies did not receive a third course of treatment in the third and fourth year.

Sanofi presented the data at the European Committee for Research and Treatment in Multiple Sclerosis (:ECTRIMS) meeting.

 Keep CURRENT and up to date, with MS News and Information


No comments: